Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Net Margin (2021 - 2025)

Historic Net Margin for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to 2.15%.

  • Verrica Pharmaceuticals' Net Margin rose 12813500.0% to 2.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 76.73%, marking a year-over-year increase of 5889000.0%. This contributed to the annual value of 976.92% for FY2024, which is 3302800.0% up from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Net Margin stood at 2.15% for Q3 2025, which was up 12813500.0% from 1.61% recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Net Margin registered a high of 1.61% during Q2 2025, and its lowest value of 17808.11% during Q1 2023.
  • For the 5-year period, Verrica Pharmaceuticals' Net Margin averaged around 2984.42%, with its median value being 1045.07% (2023).
  • As far as peak fluctuations go, Verrica Pharmaceuticals' Net Margin tumbled by -158429100bps in 2023, and later soared by 172770100bps in 2024.
  • Verrica Pharmaceuticals' Net Margin (Quarter) stood at 7.8% in 2021, then crashed by -111608bps to 8713.24% in 2022, then surged by 86bps to 1239.89% in 2023, then tumbled by -218bps to 3940.12% in 2024, then skyrocketed by 100bps to 2.15% in 2025.
  • Its Net Margin was 2.15% in Q3 2025, compared to 1.61% in Q2 2025 and 290.67% in Q1 2025.